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Abstract 
 
Peptide YY (PYY) is best known for its important role in appetite regulation, but recent 
pharmacological studies have suggested that PYY is also involved in regulating energy 
balance and glucose homeostasis. However, the mechanism behind the regulation of these 
parameters by PYY is less clear. Here, by utilising an inducible transgenic mouse model 
where PYY overexpression is induced in adult animals (PYYtg) and release of mature PYY 
peptides is controlled by endogenous machineries, we show that elevating PYY levels leads 
to reduced food intake after a 24-h fast. Furthermore, PYYtg mice, although not significantly 
different from WT with respect to body weight, adiposity, lean mass, physical activity or 
energy expenditure, exhibited a significantly increased respiratory exchange ratio (RER), 
indicating decreased lipid oxidation and/or increased lipogenesis. Importantly, PYYtg mice 
showed a 25% reduction in liver protein levels of phosphorylated acetyl-CoA carboxylase 
(pACC) in the absence of changes in total ACC levels compared to those of WT mice. 
Moreover, liver protein levels of AMP-activated kinase (AMPK) in PYYtg mice were 25% 
lower than those of WT mice, consistent with a reduced pACC in these mice. These data 
suggest that elevation of PYY levels as seen after a meal can increase lipogenic capacity, 
which is likely a key contributor to the increased RER seen in PYYtg mice. In addition, PYYtg 
mice exhibited comparable insulin tolerance and oral glucose tolerance to those of WT, but 
showed a trend towards decreased insulin levels in response to an oral glucose challenge, 
indicating that PYY could improve insulin action. Taken together, these findings demonstrate 
that under physiological conditions, PYY reduces food intake while enhancing lipogenic 
capacity and insulin action, likely contributing to fuel assimilation in the postprandial state. 
1. Introduction 	  
Obesity and type 2-diabetes mellitus are two major current public health challenges. Gut-
derived hormones play a crucial role in the regulation of body weight and glucose 
homeostasis, thus have been of major interest as possible targets for the treatment of obesity 
and type-2 diabetes. One of these hormones is peptide YY (PYY), which has been 
recognized as an important mediator of satiety and which may play a role in the aetiology of 
obesity and type-2 diabetes (Batterham et al., 2003, Roth et al., 2005, Boey et al., 
2006a and le Roux et al., 2006). 
 PYY belongs to the neuropeptide Y (NPY) family, which includes NPY and pancreatic 
polypepetide (PP). All three peptides signal through a set of G-protein-coupled Y receptors 
(Y1, Y2, Y4, Y5 and y6), which are widely expressed centrally as well as peripherally 
(Blomqvist and Herzog, 1997 and Zhang et al., 2011). PYY is primarily released from 
endocrine L cells of the lower gastrointestinal tract in proportion to the amount of calories 
ingested (Adrian et al., 1986, Batterham et al., 2002 and Ekblad and Sundler, 2002). A recent 
study shows that PYY is also synthesized by cells in the taste buds of the tongue, and this 
has important implications for the induction of satiety (Acosta et al., 2011). In the circulation, 
two forms of PYY exist; the full-length PYY1-36, and the truncated form, PYY3-36, which is 
cleaved from PYY1-36 by the specific cell surface enzyme dipeptidyl peptidase-IV (DPPIV) 
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(Mentlein, 1999 and Unniappan et al., 2006). The conversion of PYY1-36 to PYY3-36 is 
enhanced after meal ingestion, with PYY3-36 contributing to approximately 37% of circulating 
total PYY in the fasted state and 63% in the fed state (Grandt et al., 1994). Importantly, 
PYY1-36 binds to all known Y receptors, albeit to each with differing affinity, whereas PYY3-
36 preferentially binds to Y2 and to a lesser extent also Y5 receptors (Blomqvist and Herzog, 
1997). 
 Acute peripheral administration of PYY3-36 has been demonstrated to reduce food 
intake in both lean and obese animals and humans (Batterham et al., 2002, Pittner et al., 
2004, Koegler et al., 2005, le Roux et al., 2006 and Field et al., 2010). In diet-induced obese 
rodents, PYY3-36 has also been shown to promote lipid oxidation and/or reduce lipogenesis 
(Adams et al., 2006 and van den Hoek et al., 2007), as well as to enhance insulin-mediated 
glucose disposal (van den Hoek et al., 2004, van den Hoek et al., 2007, Boey et al., 
2006a and Boey et al., 2006b), further demonstrating the potential therapeutic value of PYY3-
36 in the treatment of obesity and type-2 diabetes. The mechanism underlying these effects 
of PYY3-36 on lipid metabolism and glucose homeostasis remains to be elucidated. However, 
with respect to effects on food intake, it has been shown that PYY3-36 acts on Y2 auto-
receptors on NPY neurons in the arcuate nucleus of the hypothalamus to reduce NPY-ergic 
activity and thereby induce satiety (Batterham et al., 2002 and Acuna-Goycolea and van den 
Pol, 2005). 
 In contrast to great research efforts investigating effects of PYY3-36, little attention 
has been paid to the role of PYY1-36, or the possible interactions between PYY1-36 and 
PYY3-36, in the regulation of energy balance and glucose homeostasis. PYY1-36 might be 
expected to have a broader and more complex profile of effects, since in addition to having a 
higher affinity for Y2 receptors than PYY3-36, it also has a high affinity for other Y receptors, 
such as the Y1 receptor, which elicits prominent but differential effects on energy balance and 
glucose homeostasis compared to Y2 receptor (Shi et al., 2010, Zhang et al., 2011, Shi et al., 
2011, Zhang et al., 2010b and Zhang et al., 2010c). For instance, lack of Y1 signalling 
promotes lipid oxidation (Henry et al., 2005 and Zhang et al., 2010b), whereas lack of Y2 
signalling appears to have opposite effects on oxidative fuel selection (Shi et al., 2010, Shi et 
al., 2011 and Zhang et al., 2010c). Furthermore, Y1 receptor deficiency leads to pronounced 
hyperinsulinemia which is not observed in Y2 receptor deficient mice (Kushi et al., 1998, 
Sainsbury et al., 2003 and Zhang et al., 2010b), suggesting that Y1 but not Y2 signalling 
plays an important role in regulating insulin secretion. Based on the differential effects of Y1 
and Y2 signalling on energy and glucose homeostasis, and considering that PYY1-36 and 
PYY3-36 co-exist in the circulation in varying ratios depending on nutritional status (Grandt et 
al., 1994), PYY1-36 and PYY3-36 may act in a co-ordinate or synergistic manner to regulate 
energy and glucose metabolism in fasted and postprandial states. Investigating the 
physiological actions of total PYY on energy balance and glucose homeostasis is important 
for the development of PYY-based anti-obesity and anti-diabetes therapies, particularly 
considering that nausea and vomiting are common side-effects associated with PYY3-36 
treatment (Degen et al., 2005, Gantz et al., 2007, Sloth et al., 2007 and le Roux et al., 2008). 
 Understanding the physiological effects of total PYY on energy and glucose 
homeostasis is difficult to achieve by pharmacologically administrating PYY1-36, PYY3-36 or 
in combination, since pharmacological approaches are normally complicated by dosage, 
carrier and delivery route, and – more importantly – because the ratios of PYY1-36 to PYY3-
36 in the circulation show circadian changes (Grandt et al., 1994). Interestingly, a previous 
study shows that modest germline PYY overexpression induces marked resistance to diet-
induced obesity and significantly attenuates the metabolic syndrome of genetically obese 
ob/ob mice ( Boey et al., 2008). However, compensatory changes may occur during 
development in germline genetically manipulated mouse models, with high levels of PYY 
during embryogenesis actually being lethal (Yuzuriha et al., 2007). Thus, to investigate the 
physiological role of PYY in the regulation of energy balance and glucose homeostasis in the 
absence of possible compensatory changes, we generated a conditional PYY transgenic 
mouse model in which PYY overexpression is induced in adulthood, and in which post-
translational modification of PYY1-36 to PYY3-36 is achieved by the host’s own regulatory 
machinery. Moreover, the single extra copy of the PYY transcript in these transgenic mice is 
only processed to mature and functional protein in cells and tissues that have endogenous 
machineries to process pre-proPYY peptide, and is released due to endogenously-controlled 
neuronal, hormonal and meal nutrient stimulation (Onaga et al., 2002). Thus in this model, 
PYY overexpression is expected to occur only in tissues endogenously producing PYY or 
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similar peptides. Thus, these PYY transgenic mice are expected to maintain the normal 
regulation of PYY expression in response to physiological stimuli, but with a larger change in 
magnitude relative to wild type mice after induction in adult animals, thus providing more 
definitive answers as to the physiological role played by PYY in the regulation of food intake, 
energy metabolism and glucose homeostasis. 
 
 
2. Materials and methods 
 
2.1. Animals 
All research and animal care procedures were approved by the Garvan Institute / St. 
Vincent’s Hospital Animal Ethics Committee and were in agreement with the Australian Code 
of Practice for the Care and Use of Animals for Scientific Purpose. Male mice were used for 
all experiments. Mice were housed under conditions of controlled temperature (22 °C) and 
illumination (12-h light cycle, lights on at 07:00 h). All mice were fed a normal chow diet (8% 
calories from fat, 21% calories from protein, 71% calories from carbohydrate, 2.6 kcal/g; 
Gordon’s Speciality Stock Feeds, Yanderra, NSW, Australia) and were given water ad libitum 
unless otherwise stated. 
 To generate an adult-onset PYY over-expression model, heterozygote transgenic 
mice carrying an additional copy of the mouse PYY gene that is separated from a CMV 
promoter by a loxP-flanked stop cassette (PYYlox/+), were crossed with homozygous Cre 
transgenic mice (ROSACre, Jackson Laboratory, Bar Harbor, ME, USA), in which expression 
of Cre-recombinase is driven by the Rosa26 promoter in a tamoxifen-inducible manner ( 
Hayashi and McMahon, 2002). The resultant animals of this cross consist of both tamoxifen-
inducible over-expressing PYY transgenic mice (PYYlox/+,ROSACre/+) and non PYY 
overexpressing littermate controls (WT,ROSACre/+). Tamoxifen treatment of 
(PYYlox/+,ROSACre/+) mice activates Cre-recombinase expression that in turn removes the 
transcriptional stop cassette between the CMV promoter and the PYY gene, thereby allowing 
expression of the additional copy of the PYY gene in tamoxifen-responsive tissues. Upon 
tamoxifen treatment, (PYYlox/+,ROSACre/+) and (WT,ROSACre/+) mice will be referred to as 
PYYtg and WT, respectively. Tamoxifen (i.p. 100 mg/kg) was injected on two separate 
occasions 3 days apart into mice at 8 weeks of age. Metabolic studies on these mice as 
described below commenced at least 4 weeks after the induction of PYY expression. 
 
2.2. Immunohistochemical analysis 
Pancreatic tissues obtained from wild type, PYY−/− and Rosa–PYYtg mice were fixed in 4% 
paraformaldehyde in phosphate buffered saline (PBS), processed and embedded in paraffin 
and cut at 5 µm sections. Sections were deparaffinised, rehydrated and incubated in 1% H2O2 
in ethanol for 20 min to block endogenous peroxidase activity. Sections were then rinsed in 
PBS and incubated with 10% horse serum in PBS for 20 min in order to reduce non-specific 
binding. Subsequently sections were incubated overnight at 4 °C in hydration chambers with 
an in-house-generated monoclonal antibody against PYY. Slides were then rinsed in PBS 
before incubation for 30 min at room temperature with biotinylated goat anti-mouse IgG 
antibody (whole molecule) (diluted 1:500 in PBS) (Sigma–Aldrich Inc. Saint Louis, MO, USA). 
Sections were then rinsed in PBS and incubated with ExtrAvidin-Peroxidase (1:250) (Sigma–
Aldrich Inc. Saint Louis, MO, USA) for 30 min at room temperature. Sections were washed in 
PBS and treated with diaminobenzidine (DAB + Substrate Chromogen System, DAKO Corp, 
Carpinteria, CA, USA) for 5 min. Slides were rinsed in water, counterstained with 
haematoxylin and dehydrated through to xylene before coverslipping. 
 
2.3. Induction of PYY overexpression and food intake, body weight and tissue analyses 
PYY over-expression was induced by i.p. injection of tamoxifen (100 mg/kg) in PYYtg and WT 
littermate mice at 8 weeks of age. 4 weeks after the induction of PYY over-expression (at 12-
weeks of age), spontaneous daily and 24 h fasting-induced food intake were examined using 
a metabolic caging system (Techniplast, Buguggiate, VA Italy), where pellet food was used as 
that was given in the home cage. Mice were transferred from group housing on soft bedding 
to individual cages with paper towel bedding and allowed to acclimatize for 2 nights. Basal 
daily food intake was determined as the average of duplicate readings taken over 2 
consecutive days. For fasting-induced food intake, mice were fasted for 24 h and food intake 
was determined at 2, 4, 8, 24 and 48 h after the re-feeding. At 17 weeks of age, animals were 
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culled between 1200–1500 h by cervical dislocation followed by decapitation. White adipose 
tissue depots (right inguinal, right epididymal, mesenteric and right retroperitoneal) and the 
entire interscapular brown adipose tissue depot were removed and weighed as published 
previously (Sainsbury et al., 2002 and Zhang et al., 2010b). 
 
2.4. Determination of metabolic rate, respiratory exchange ratio and physical activity 
Energy metabolism was studied in 15 week-old male PYYtg, PYY−/− and wild type mice. 
Metabolic rate was measured by indirect calorimetry using an eight-chamber open-circuit 
calorimeter (Oxymax Series; Columbus Instruments, Columbus, OH, USA) as described 
previously (Zhang et al., 2010b). Briefly, mice were housed individually in specially built 
Plexiglas cages (20.1 × 10.1 × 12.7 cm). Temperature was maintained at 22 °C with airflow of 
0.6 l/min. Mice were singly housed for at least 3 days prior to transferring into plexiglass 
cages and were acclimatized to the cages for 24 h before recordings commenced. Mice were 
subsequently monitored in the system for 24 h. Pellet food was used when mice were in 
metabolic chambers, and excess amount food was given prior to the data collection so that 
no food needs to be re-introduced during the recording. Oxygen consumption (VO2) and 
carbon dioxide production (VCO2) were measured every 27 min. The respiratory exchange 
ratio (RER) was calculated as the quotient of VCO2/VO2, with 100% carbohydrate oxidation 
giving a value of 1, and 100% fat oxidation giving value of 0.7 ( Frayn, 1983 and Ferrannini, 
1988). Energy expenditure (kcal heat produced) was calculated as Calorific Value 
(CV) × VO2, where CV is 3.815 + 1.232 × RER (McLean and Tobin, 1987). Data for the 24-h 
monitoring period was averaged for 1-h intervals for energy expenditure and RER. 
Ambulatory activity of individually-housed mice was evaluated within the metabolic chambers 
using an OPTO-M3 sensor system (Columbus Instruments, Columbus, OH, USA), whereby 
ambulatory counts were a record of consecutive adjacent photo-beam breaks. Cumulative 
ambulatory counts of X and Y directions were recorded every minute and summed for 1-h 
intervals. 
 
2.5. Analysis of body composition 
Upon completion of indirect calorimetry and physical activity measurements, animals were 
anesthetized with isoflurane and then scanned for whole-body lean and fat mass using Dual-
energy X-ray absorptiometry (DEXA, Lunar PIXImus2 mouse densitometer; GE Healthcare, 
Waukesha, WI, USA). The head and the tail were excluded from DEXA analyses. Fat mass at 
the anterior abdominal region between the xiphisternal joint to the inferior end of the rib cage 
was analyzed from DEXA scans as the indication of the hepatic fat mass, since liver is the 
major organ residing in the anterior abdominal cavity (Cook, 1965). 
 
2.6. Oral glucose tolerance test 
Oral glucose tolerance test was performed in a subset of male PYYtg and wild type mice at 
18–20 weeks of age. An oral glucose bolus was given as a glucose jelly, which was 
consumed voluntarily by mice within 1 min. To achieve this, we trained mice to voluntarily eat 
a vehicle jelly that would contain glucose on the day of experimentation. Training and vehicle 
jelly preparation were as described previously (Cox et al., 2010 and Zhang et al., 2010a). 
Mice were fasted at 2 pm prior to testing day for 24 h and were then given an oral glucose 
bolus (3 g/kg body weight) at 2 pm on the testing day. Glucose (0.52 g/mL) was incorporated 
into a jelly containing 4.9% wt/vol gelatin and 7.5% imitation strawberry flavouring essence. 
Tail vein blood was collected at 0, 5, 15, 30, 60 and 120 min after the mouse had finished 
eating the glucose jelly, and blood was collected for the determination of glucose and insulin 
levels as described below. Glucose tolerance curves for glucose and insulin are presented as 
absolute values. Area under the glucose or insulin concentration curves between 0 and 
120 min after glucose ingestion were calculated, subtracting glucose or insulin concentrations 
prior to glucose ingestion. 
 
2.7. Intraperitoneal insulin tolerance test 
A subset of PYYtg and wild type male mice at 18–20 weeks of age were used for this study. 
Food was removed from cage hoppers at 8.30 h, and 5–6 h later a dose of insulin (0.75 IU/kg 
body weight, Actrapid, Novo Nordisk, Baulkham Hills, NSW, Australia) was injected into the 
peritoneal cavity. Approximate 5 µL blood was taken from the tip of the tail at 0, 15, 30, 45, 60 
and 75 min after insulin injection for determination of blood glucose concentration using a 
glucometer (Accu-Check Go, Roche). 
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2.8. Serum analyses 
Serum insulin levels were measured using an RIA kit from Mercodia (Uppsala, Sweden). 
Serum glucose in samples collected during oral glucose tolerance tests was determined by a 
glucose oxidase kit (Trace Scientific, Melbourne Australia). 
 
2.9. Western blotting 
Western blotting was performed on liver and quadriceps muscle samples following 
procedures described previously (Zhang et al., 2010b) in order to determine protein levels of 
key enzymes involved in lipid metabolism. Briefly, liver and quadriceps muscles were 
collected from 20 week-old WT and PYYtg mice, snap frozen in liquid nitrogen and stored at 
−80 °C. Subsequently, liver and powdered muscle samples were resuspended in 
radioimmunoprecipitation assay buffer (PBS, pH–7.5; 1% nonident NP-40; 0.5% sodium 
deoxy-cholate; and 0.1% SDS), supplemented with protease and phosphatase inhibitors 
(10 µg/ml phenylmethylsulfonyl fluoride, 10 µg/ml aprotinin, 10 µg/ml leupeptin, 
1 mmol/l Na3VO4, and 10 mmol/l NaF) and solubilized for 2 h at 4 °C. Equal amounts of tissue 
lysate (20 µg protein) were resolved by SDS–PAGE and immunoblotted with antibodies 
against carnitine palmitoyltransferase-1 (CPT-1) (Alpha Diagnostic Intl., San Antonio, Texas, 
USA), AMP-activated kinase (AMPK, Cell Signalling Technology, Danves, MA, USA), 
phospho-Ser79 acetyl-CoA carboxylase (pACC) and total acetyl-CoA carboxylase (tACC) 
(Cell Signalling Technology, Danvers, MA, USA). Immunolabelled bands were quantitated by 
densitometry. Relative protein levels of the mutant mice as a percentage of that of control 
mice are presented. 
 
2.10. Statistical analyses 
All data are expressed as means ± SEM. RER and physical activity over the continuous 24-h 
period were averaged for the whole 24-h period, as well as for the light and dark periods. 
Differences between different genotypes were assessed by ANOVA or repeated-measures 
ANOVA. Comparisons of energy expenditure (kcal/h) were carried out by analysis of 
covariance (ANCOVA) with lean body mass as the covariates. The adjusted means of energy 
expenditure at a common lean mass for the comparison were generated by ANCOVA. 
Multiple food intake measurements after a 24-h fast were analysed by repeated-measures 
ANOVA. Statistical analyses were performed with SPSS for Mac OS X, version 16.0.1 (SPSS 
Inc., Chicago, IL, USA). Statistical significance was defined as P < 0.05. 
 
3. Results 
 
3.1. Adult-onset PYY overexpression reduces food intake 
Transgenic mice carrying an additional copy of the mouse PYY gene, separated from a CMV 
promoter by a loxP-flanked stop cassette (PYYlox/+), were crossed with mice carrying the 
gene for Cre recombinase. The Cre recombinase gene was under the control of a tamoxifen-
sensitive promoter (ROSACre), leading to the generation of (PYYlox/+,ROSACre/+) mice. 
Overproduction of PYY in adult mice was achieved by intraperitoneal injection of tamoxifen 
(100 mg/kg) into 8 week-old (PYYlox/+,ROSACre/+) mice on two separate occasions, 3 days 
apart. 
 In order to confirm successful deletion of the stop cassette in front of the additional 
PYY gene, we employed PCR on genomic DNA isolated from liver tissue at 3 weeks after 
tamoxifen treatment, using primers that only amplify a product when the stop cassette has 
been removed. Production of a fragment of the expected size was only obtained in the 
tamoxifen-treated mice but not in the saline control treated mice (data not shown). We also 
performed immunohistochemistry using a monoclonal antibody specific to PYY in order to 
detect elevated PYY levels in target tissues such as the pancreas. The specificity of this 
antibody is demonstrated by the lack of PYY staining in pancreas tissue obtained from PYY−/− 
mice (Fig. 1A). Importantly, the cells stained for PYY in pancreatic tissue from tamoxifen-
induced (PYYlox/+,ROSACre/+) mice were much darker and significantly greater in number 
compared to those from (WT,ROSACre/+) control pancreatic tissue (Fig. 1A), confirming the 
successful induction of PYY overexpression. 
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   Prior to tamoxifen injection at 8 weeks of age, body weight was comparable between 
(PYYlox/+,ROSACre/+) and littermate control (WT,ROSACre/+) mice (Fig. 1B). Upon injection 
of tamoxifen to induce PYY over-expression, PYYtg mice showed a similar growth curve to 
that of WT mice (Fig. 1B). Whole body lean and fat mass determined by DEXA scan at 
7 weeks after the induction of PYY overexpression (when mice were 15 weeks old) were 
comparable between PYYtg and WT mice (Fig. 1C). Moreover, weights of the dissected 
individual and total summed weight of these individual white adipose tissue depots, namely 
the inguinal, epidydimal, mesenteric and retroperitoneal white adipose tissue depots, were 
not significantly different between the transgenic and the WT groups (Fig. 1D), consistent with 
whole body adiposity results obtained by DEXA scan (Fig. 1B). Interestingly, spontaneous 
daily food intake tended to be decreased in PYYtg compared to WT littermates (4.20 ± 0.21 
versus 4.62 ± 0.13 g/day for PYYtg and WT mice, respectively, data are mean ± SEM of 6–13 
mice per group, P = 0.098). Importantly, after a 24 h fast, PYYtg mice consumed significantly 
less food than WT mice during the 48 h re-feeding period (P < 0.05 for PYYtg versus WT 
mice by repeated ANOVA measures, data are mean ± SEM of 6–13 mice per group) (Fig. 
overexpression, we determined the protein levels of carnitine
palmitoyltransferase-1 (CPT-1), the mitochondrial transmembrane
enzyme controlling entry of fatty acid into mitochondria and the
rate-limiting enzyme for fatty acid oxidation (Saggerson and
Carpenter, 1981; McGarry et al., 1983). There was no significant
difference in the liver or muscl CPT-1 protein expression between
PYYtg and WT mice (Fig. 2G), indicating unaltered fatty acid oxida-
tive capacity by PYY overexpression. Taken together, these data
show that PYY plays a critical role in regulating lipid metabolism,
and that elevated PYY levels increase lipogenic capacity. This
may be the major contributor to the increased respiratory ex-
change ratio seen in PYYtg versus WT mice.
3.4. Adult-onset PYY overexpression enhances insulin action
We performed intraperitoneal insulin tolerance tests and oral
glucose tolerance tests in PYYtg and WT mice to investigate the ef-
fect of levated PYY on glucose homeostasis. Blood glucose concen-
trations before insulin injection or oral glucose bolus were
comparable between PYYtg and WT mice in both fasting and non-
fasting states (fasting: 6.9 ± 0.29 and 7.3 ± 0.4 mM forWTand PYYtg
mice respectively; non-fasting: 11.2 ± 0.33 and 10.8 ± 0.26 mM for
WT and PYYtg mice, respectively; data are means ± SEM from 4–6
mice per group, ns). After insulin injection (0.75 U/kg), PYYtg mice
showed similar blood glucose r ponses to that of WT mice
Fig. 1. Effects of adult-onset PYY overexpression on body weight, body composition and fasting-induced food intake. (A) Representative picture of immunohistochemical
staining of PYY in pancreatic tissue from 18–20 week-old male wild type (WT), inducible PYY transgenic (PYYtg) and PYY knockout (PYY!/!) mice. Scale bar in (A) represents
50 lm. (B) Body weight curve in WT and PYYtg mice. (C) Whole body fat mass (FM) and lean mass (LM) as determined by dual-energy X-ray absorptiometry in WT and PYYtg
mice at 15 weeks of age. (D) Weights of individual and summed (total) white adipose depots, namely inguinal (i), epididymal (e), mesenteric (m) and retroperitoneal (r), from
WT and PYYtg mice at 17 weeks of age. (E) Food intake after a 24-h fast in WT and PYYtg mice. Food intake measurements at 2, 4, 8, 24 and 48 h after re-feeding in (E) were
analysed by repeated-measures ANOVA as indicated by the bar over the multiple measurements during the 48-h period. Data are means ± SEM of 6–8 mice per group.
⁄P < 0.05 versus WT mice.
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1E), demonstrating the important role of PYY in the regulation of food intake. Taken together, 
these results show that whereas over-expressing PYY during adulthood does not significantly 
alter body weight or adiposity, it reduces food intake, particularly under conditions associated 
with increased appetite, namely after fasting. 
 
3.2. Adult-onset overexpression of PYY increases respiratory exchange ratio 
To investigate the role of PYY in the regulation of energy metabolism, we performed indirect 
calorimetry with concurrent measurement of physical activity in PYYtg and WT mice. Physical 
activity (Fig. 2A), energy expenditure (Fig. 2C) and respiratory exchange ratio (Fig. 2E), an 
index of oxidative fuel source, showed circadian rhythms in both PYYtg and WT mice, with 
increased levels in all parameters during the dark phase. Moreover, the circadian patterns as 
well as the values of physical activity and energy expenditure were similar between PYYtg 
and WT mice (Fig. 2A–D). Interestingly, however, PYYtg mice showed a significantly higher 
respiratory exchange ratio during the light period compared to WT mice (Fig. 2E and F), 
suggesting decreased lipid oxidation and/or increased lipogenesis in mice with elevated PYY 
levels. 
 
 
(Fig. 3A and B), suggesting an unaltered response to insulin by PYY
overexpression, at least at the dose used. Upon a voluntary oral glu-
cose bolus, PYYtg mice exhibited a similar blood glucose excursion
and a comparable area under the resultant glucose curve toWTmice
(Fig. 3C andD). Interestingly however, serum insulin concentrations
after the oral glucose bolus tended to be lower in the PYYtg mice
(Fig. 3E), with the area under the resultant insulin curve showing
a trend to be decreased in PYYtg compared to WT mice (P = 0.1)
(Fig. 3F). Taken together, these results show that adult-onset PYY
overexpression does not significantly alter insulin or glucose toler-
ance, however, it may enhance insulin action on target tissues.
4. Discussion
In this study, we used an adult-onset PYY over-expression
mouse model and demonstrated that chronic elevation of PYY
Fig. 2. Effects of adult-onset PYY overexpression on energy metabolism and protein levels of key enzymes involved in lipid metabolism and hepatic fat mass. Physical activity
(A, B), energy expenditure (C, D) and respiratory exchange ratio (E, F) in male wild type (WT) and inducible PYY transgenic (PYYtg) mice at 15 weeks of age. A, C and E
represent the time course for each parameter over 24 h, with open and filled horizontal bars indicating the light and dark phases, respectively. B, D and F represent averages
for 24-h, light and dark phases for each parameter. For comparison of energy expenditure by analysis of covariance, the common lean mass was 21.88 g. (G) Protein levels of
total acetyl-CoA carboxylase (tACC), phospho-Ser79 acetyl-CoA carboxylase (pACC), AMP-activated kinase (AMPK) and carnitine palmitoyltransferase-1 (CPT-1) in liver, and
protein levels of CPT-1 in skeletal muscle from 20 week-old male wild type (WT) and inducible PYY transgenic (PYYtg) mice. (H) Hepatic fat mass was determined by DEXA
scan with region-of-interest frame located at the anterior abdominal region between the xiphisternal joint to the inferior end of the rib cage where liver resides. Data in (G)
are normalized to WT values. Data are means ± SEM of 4–7 mice per group. ⁄P < 0.05 versus WT mice.
178 Y.-C. Shi et al. / Neuropeptides 46 (2012) 173–182
Shi	  YC	  et	  al.:	  /	  Neuropeptides	  46(4):	  173-­‐82,	  2012	  	  
3.3. Adult-onset overexpression of PYY increases lipogenic capacity 
To elucidate pathways via which PYY increases respiratory exchange ratio, we examined 
protein expression of key molecules involved in the control of lipid metabolism by Western 
blotting. We determined the liver protein levels of total acetyl-CoA carboxylase (tACC), the 
enzyme catalysing the regulatory step for fatty acid synthesis, as well as the hepatic level of 
phosphorylated ACC (pACC), since the activity of ACC is negatively regulated by 
phosphorylation at ser-79/218 (Ruderman et al., 2003). Whereas there was no significant 
difference in the liver protein levels of tACC between PYYtg and WT mice, the protein levels 
of pACC were reduced by 25% in PYYtg compared to WT mice (Fig. 2G), suggesting a higher 
level of active ACC enzyme and thus an increased lipogenic capacity in mice with elevated 
PYY levels. Moreover, consistent with the significant reduction in ACC phosphorylation by 
PYY overexpression, liver protein levels of AMP-activated protein kinase (AMPK), the 
enzyme that phosphorylates and inactivates ACC, was 25% lower in PYYtg compared to WT 
mice (Fig. 2G). Interestingly, the fat mass determined by DEXA scan at the anterior 
abdominal region where liver resides was not significantly different between PYYtg and WT 
mice (Fig. 2H), indicating the increased lipogenic capacity by PYY overexpression may not 
lead to an increased hepatic adiposity. To investigate whether the capacity for fatty acid 
oxidation was also increased by PYY overexpression, we determined the protein levels of 
carnitine palmitoyltransferase-1 (CPT-1), the mitochondrial transmembrane enzyme 
controlling entry of fatty acid into mitochondria and the rate-limiting enzyme for fatty acid 
oxidation (Saggerson and Carpenter, 1981 and McGarry et al., 1983). There was no 
significant difference in the liver or muscle CPT-1 protein expression between PYYtg and WT 
mice (Fig. 2G), indicating unaltered fatty acid oxidative capacity by PYY overexpression. 
Taken together, these data show that PYY plays a critical role in regulating lipid metabolism, 
and that elevated PYY levels increase lipogenic capacity. This may be the major contributor 
to the increased respiratory exchange ratio seen in PYYtg versus WT mice. 
 
3.4. Adult-onset PYY overexpression enhances insulin action 
We performed intraperitoneal insulin tolerance tests and oral glucose tolerance tests in PYYtg 
and WT mice to investigate the effect of elevated PYY on glucose homeostasis. Blood 
glucose concentrations before insulin injection or oral glucose bolus were comparable 
between PYYtg and WT mice in both fasting and non-fasting states (fasting: 6.9 ± 0.29 and 
7.3 ± 0.4 mM for WT and PYYtg mice respectively; non-fasting: 11.2 ± 0.33 and 
10.8 ± 0.26 mM for WT and PYYtg mice, respectively; data are means ± SEM from 4–6 mice 
per group, ns). After insulin injection (0.75 U/kg), PYYtg mice showed similar blood glucose 
responses to that of WT mice (Fig. 3A and B), suggesting an unaltered response to insulin by 
PYY overexpression, at least at the dose used. Upon a voluntary oral glucose bolus, PYYtg 
mice exhibited a similar blood glucose excursion and a comparable area under the resultant 
glucose curve to WT mice (Fig. 3C and D). Interestingly however, serum insulin 
concentrations after the oral glucose bolus tended to be lower in the PYYtg mice (Fig. 3E), 
with the area under the resultant insulin curve showing a trend to be decreased in PYYtg 
compared to WT mice (P = 0.1) (Fig. 3F). Taken together, these results show that adult-onset 
PYY overexpression does not significantly alter insulin or glucose tolerance, however, it may 
enhance insulin action on target tissues. 
 
4. Discussion 
 
In this study, we used an adult-onset PYY over-expression mouse model and demonstrated 
that chronic elevation of PYY levels has significant effects on energy homeostasis, since 
PYYtg mice exhibit significantly reduced fasting-induced food intake and increased 
respiratory exchange ratio. These results are indicative of decreased lipid oxidation and/or 
increased lipogenesis, albeit there were no significant changes in body weight, adiposity, 
physical activity or energy expenditure. The increased respiratory exchange ratio with PYY 
overexpression is likely due to increased lipogenic capacity, since PYYtg mice show 
significantly reduced phosphorylation of liver ACC, the enzyme catalysing a key regulatory 
step of fatty acid synthesis, and the activity of which is negatively regulated by 
phosphorylation (Ruderman et al., 2003). The capacity for lipid oxidation, on the other hand, 
may not be altered with PYY overexpression, since PYYtg and WT mice have comparable 
liver or muscle protein levels of CPT-1, the rate-limiting enzyme for lipid oxidation (Saggerson 
and Carpenter, 1981 and McGarry et al., 1983). Moreover, although equally glucose tolerant, 
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PYYtg mice show a trend towards reduced serum insulin levels in response to an oral 
glucose bolus, suggesting enhanced insulin action in peripheral tissues. Finally, it is important 
to note that these effects are being observed on a lean background and might be more 
pronounced under obesifying conditions. 
 
 Our data suggest that elevating PYY levels may have a long-term effect in reducing 
appetite, particularly in suppressing the enhanced appetite induced by a period of energy 
deficit. It is noteworthy that the effect of chronic peripheral PYY3-36 administration to reduce 
spontaneous food intake is transient, lasting only for the first few days of administration 
(Adams et al., 2006, Vrang et al., 2006, Ortiz et al., 2007 and van den Hoek et al., 2007). Y 
receptor down-regulation due to constant stimulation by continuously elevated PYY is 
suggested to contribute to transient feeding responses to continuous administrations of 
PYY3-36 (Chelikani et al., 2006). Furthermore, and perhaps more importantly, 
pharmacological administration of PYY3-36 only targets Y2 receptors and does not affect Y1 
receptor signalling, which is still a component of the endogenously-elicited physiological 
effects by PYY. In this regard, although not statistically significant, the lower spontaneous 
food intake observed in our PYYtg mouse model, where transgene PYY is expressed and 
secreted in the same way as endogenous PYY, thus maintaining the normal meal-associated 
release rhythm and proportional production of full-length and truncated form of PYY peptides, 
suggests that the rhythmic release of PYY as well as a combined activation of both Y1 and 
Y2 receptors might be critical for a balanced and continuous control of food intake. In keeping 
with the former notion, recent studies show that administrating PYY3-36 intermittently in rats 
lead to a sustained reduction in daily food intake (Chelikani et al., 2006 and Chelikani et al., 
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phosphorylation of liver ACC, the enzyme catalysing a key regula-
tory step of fatty acid synthesis, and the activity of which is nega-
tively regulated by phosphorylation (Ruderman et al., 2003). The
capacity for lipid oxidation, on the other hand, may not be altered
with PYY overexpression, since PYYtg and WT mice have compara-
ble liver or muscle protein levels of CPT-1, the rate-limiting en-
zyme for lipid oxidation (Saggerson and Carpenter, 1981;
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Our data suggest that elevating PYY levels may have a long-
term effect in reducing appetite, particularly in suppressing the en-
hanced appetite induced by a period of energy deficit. It is note-
worthy that the effect of chronic peripheral PYY3-36
administratio to red ce spontaneous food intake is transient, last-
ing only for the first few days of administration (Adams et al.,
2006; Vrang et al., 2006; Ortiz et al., 2007; van den Hoek et al.,
2007). Y receptor down-regulation due to constant stimulation
by continuously elevated PYY is suggested to contribute to tran-
sient feeding responses to continuous administrations of PYY3-36
(C elikani et al., 2006). Furthermore, and perhaps more impor-
tantly, pharmacological administration of PYY3-36 only targets
Y2 receptors and does not affect Y1 receptor signalling, which is
still a component of the endogenously-elicited physiological ef-
fects by PYY. In this regard, although not statistically significant,
the lower spontaneous food intake observed in our PYYtg mouse
model, where transgene PYY is expressed and sec eted in the same
Fig. 3. Effects of adult-onset PYY overexpression on oral glucose and insulin tolerance. Blood glucose levels (A) and the change in blood glucose levels as a percent of basal
values (B) during a 75-min intraperitoneal insulin tolerance test (0.75 U/kg) in male wild type (WT) and inducible PYY transgenic (PYYtg) mice at 18–20 weeks of age. Serum
glucose levels (C) and area under the resultant glucose curve (D), serum insulin levels (E) and area under the resultant insulin curve (F) during a 120-min oral glucose
tolerance test (3 g/kg). Glucose was given as a glucose jelly that was voluntarily consumed within 1 min after which t = 0 by each mouse. Data are means ± SEM of 4–6 mice
per group. ⁄P < 0.05 versus WT mice.
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2007). Importantly, our data show a more pronounced reduction in food intake in PYYtg 
versus WT mice after a 24-h fast than in the non-fasted state, suggesting a potent action of 
PYY in suppressing hyperphagic responses induced by a period of negative energy balance. 
This finding has important clinical implications, since negative energy balance, a prerequisite 
for weight loss, is known to enhance hunger and is a significant predictor for subsequent 
weight regain (Sainsbury and Zhang, 2010 and Sainsbury and Zhang, 2011). Thus, PYY-
based anti-obesity therapy may be particularly effective during the weight maintenance period 
in post-obese people, by controlling hyperphagia. In addition, PYY released from the gut is 
also thought to act as an “ileal brake” that slows intestinal transit, thereby inducing satiety 
(Savage et al., 1987, Lin et al., 1996 and Maljaars et al., 2008). This effect of PYY has 
recently been shown to involve interactions with NPY, which increases gastric emptying via 
central mechanism (Chen et al., 1997, Monnikes et al., 2000 and Tough et al., 2011). These 
findings that PYY interacts with NPY to exert its anorexic effects are in accordance with the 
marked reduction in fasting-induced food intake observed in our PYYtg mice, since energy 
deficit, such as that induced by fasting, enhances hypothalamic NPY expression and NPY 
central actions (Sainsbury and Zhang, 2010). 
 Our data also demonstrate that PYY is an important player in the regulation of 
oxidative substrate metabolism, with increasing PYY levels leading to an increased 
respiratory exchange ratio. It is worth to note that an increase in food intake can potentially 
enhance respiratory exchange ratio. Since the non-locomotion activity of a mouse in the 
metabolic chamber may be suggestive of feeding, we conducted an analysis of non-
locomotive counts (subtracting the ambulatory counts from the total counts of photo-beam 
breaks) as a measure of non-locomotion activity to examine whether an increased feeding 
behaviour in PYYtg versus WT mice could be identified during the light period when the 
increased respiratory exchange ratio was observed. This analysis showed a comparable non-
locomotion activity between PYYtg and WT mice (data not shown), lending no support to the 
possible contribution of an increased light-phase feeding to the increase in light-phase 
respiratory exchange ratio in the PYYtg mice. Importantly, our results show that this effect 
may have been caused by an enhanced lipogenic capacity in our PYYtg mice. As fatty acid 
oxidative capacity seems unaltered by PYY overexpression, as indicated by the comparable 
liver and muscle CPT-1 protein levels between PYYtg and WT mice, decreased lipid oxidation 
seems unlikely to have contributed to the increased respiratory exchange ratio observed in 
PYYtg mice. PYY overexpression may enhance respiratory exchange ratio and lipogenic 
capacity by activating Y1 signalling, since lack of Y1 signalling either in the germline, or only 
in peripheral tissues of adult mice, results in significant decreases in respiratory exchange 
ratio (Zhang et al., 2010b). Interestingly, in contrast to Y1 signalling-mediated effects, 
activation of Y2 signalling promotes lipid oxidation and/or inhibition of lipogensis, since 
conditional knockdown of Y2 signalling in the periphery of adult mice leads to significantly 
increased respiratory exchange ratio (Shi et al., 2011). This is in accordance with 
pharmacological studies showing that peripheral administration of PYY3-36, which 
preferentially activates Y2 receptors, mobilizes fatty acids and enhances fatty acid oxidation 
(Adams et al., 2006 and van den Hoek et al., 2007). Our finding that PYY overexpression 
leads to significantly increased respiratory exchange ratio suggests that the lipogenic activity 
mediated by PYY1-36 via Y1 signalling is more potent than the lipolytic activity mediated by 
PYY1-36 and PYY3-36 via Y2 signalling. Considering that PYY is released postprandially and 
remains elevated during the absorptive phase (Adrian et al., 1986 and Ekblad and Sundler, 
2002), the lipogenic and anti-lipolytic properties of total PYY may facilitate nutrient 
incorporation and storage. 
 Glucose and insulin tolerance were not significantly altered in our PYYtg compared to 
WT mice. It is worth to note however that the 24-h fasting period prior to oral glucose 
administration may have led to underestimation of any potential effect of PYY overexpression 
on glucose clearance, since it was recently shown that the duration of fasting has a significant 
impact on fasting and glucose-induced circulating glucose levels, and an impaired glucose 
tolerance induced by high fat diet feeding in mice was more apparent with a 6-h versus a 24-h 
fast regime (Andrikopoulos et al., 2008). Interestingly, serum insulin levels in PYYtg mice 
showed a trend towards decreased levels after an oral glucose bolus relative to WT mice, 
suggesting enhanced insulin action. In keeping with reduced insulin output and improved 
insulin action by PYY transgenic overexpression, mice with PYY deficiency exhibit marked 
elevations in glucose-stimulated serum insulin levels and glucose output without changes in 
circulating glucose excursions compared to WT mice (Boey et al., 2006b). Moreover, low 
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serum PYY levels are associated with increased insulin secretion and insulin resistance in 
humans (Boey et al., 2006a). Pharmacological studies show that during hyperinsulinemic–
euglycemic clamp, peripheral administration of PYY3-36 enhances insulin-stimulated glucose 
uptake in muscle and adipose tissue in mice fed a high fat diet, suggesting a mechanism 
involving Y2 signalling (van den Hoek et al., 2004 and van den Hoek et al., 2007). It is 
interesting to note that this PYY-induced enhancement in insulin-stimulated glucose uptake in 
peripheral tissues may synergize with its lipogenic action, and would be in keeping with the 
notion that postprandial release of PYY facilitates nutrient uptake and storage. Importantly, 
our results showing that elevating PYY levels in mice in adulthood may enhance insulin action 
are consistent with a long-term role of PYY in the regulation of glucose homeostasis and 
insulin sensitivity, and lend further support to the notion that PYY-based therapies have the 
therapeutic potential to treat type 2 diabetes (van den Hoek et al., 2004, van den Hoek et al., 
2007, Boey et al., 2006a and Boey et al., 2006b). 
 In the current study where all mice are fed on a chow diet, mice with adult-onset PYY 
over-expression are not significantly different from WT mice with regards to body weight, 
body composition, energy expenditure or physical activity. Importantly, however, the reduction 
in food intake and increase in lipogenic capacity may negate each other, resulting in the 
unaltered body weight and adiposity despite hypophagia in PYYtg mice. Interestingly, a 
previous study showed that germline PYY transgenic mice on a high fat diet, or crossed onto 
the genetically obese ob/ob background, showed reduced adiposity and improved glucose 
tolerance compared to control mice ( Boey et al., 2008). These differences were associated 
with a significant increase in rectal temperature and resistance to diet-induced inhibition of 
hypothalamo-pituitary-thyroid axis activity (Boey et al., 2008). These changes, however, were 
not seen between groups fed on a chow diet (Boey et al., 2008). Thus it seems possible that 
obesogenic conditions, either diet- or genetically-induced, may activate stronger anti-obesity 
and anti-diabetes properties of PYY that are not seen under normal conditions. Future studies 
challenging these adult-onset PYY over-expressing mice with obesogenic conditions may 
shed further light into the therapeutic potential of PYY-based anti-obesity and anti-diabetes 
treatment. 
 In summary, we show that adult-onset PYY overexpression leads to a significant 
reduction in fasting-induced food intake, a significant increase in respiratory exchange ratio in 
association with a marked increase in lipogenic capacity, and a strong trend towards 
decreased glucose-stimulated insulin secretion without changing glucose excursion, 
suggesting improved insulin action. These results demonstrate the important roles played by 
PYY under physiological conditions in regulating energy balance and glucose homeostasis. 
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